Internistische und Rheumatologische Gemeinschaftspraxis, Gladbeck, Germany.
Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S121-5. Epub 2011 Oct 22.
Glucocorticoids (GCs) have been an invaluable tool in the treatment of patients with rheumatoid arthritis (RA) for decades, with a focus mainly on symptom management. In addition, several studies in the last 15 years have shown that GCs are also disease-modifying in patients with RA - which implies that they inhibit radiographic progression. These effects seem to be especially important in the early course of disease. Nonetheless, there is still a lack of knowledge concerning optimal therapeutic strategies with GCs, particularly regarding patient selection and optimal dosage schedules.
几十年来,糖皮质激素(GCs)一直是治疗类风湿关节炎(RA)患者的宝贵工具,主要侧重于症状管理。此外,过去 15 年来的几项研究表明,GCs 对 RA 患者也具有疾病修饰作用 - 这意味着它们抑制放射学进展。这些作用在疾病的早期阶段似乎尤为重要。尽管如此,对于 GCs 的最佳治疗策略,特别是关于患者选择和最佳剂量方案,我们仍然缺乏了解。